PharmaMar stops development of phase II compound
Enlarge image

IndustrySpain

PharmaMar stops development of phase II compound

11.04.2012 - Spanish drug developer will focus internal resources on its late-stage compounds.

Madrid – Spanish drug developer PharmaMar SA has quit the further development of its Phase II drug candidate Irvalec due to financial reasons. According to the company, the marine-derived cyclic peptide has shown notable activity in a trial to treat gastroesophageal cancer specifically in large cell undifferentiated carcinomas of the esophagus. However, this subtype is relatively rare and represents only 1% of all gastroesophageal cancers. The company, a member of listed Zeltia Group, will focus its resources on other compounds like Yondelis and Aplidin. Yondelis is approved outside the US to treat advanced or metastatic soft tissue sarcoma and relapsed platinum-sensitive ovarian cancers. The conotoxin has additionally been tested as first-line therapy for this indication. Aplidin is in phase III to treat multiple myeloma and in phase II for T-cell lymphoma.

http://www.european-biotechnology-news.com/news/news/2012-02/pharmamar-stops-development-of-phase-ii-compound.html

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.47 CHF27.03%
  • BIOFRONTERA2.07 EUR4.02%
  • FORMYCON17.40 EUR3.02%

FLOP

  • STRATEC BIOMEDICAL43.50 EUR-3.59%
  • MEDIGENE4.55 EUR-1.94%
  • EVONIK30.88 EUR-1.66%

TOP

  • WILEX3.15 EUR47.9%
  • CYTOS0.47 CHF38.2%
  • EVOLVA1.69 CHF18.2%

FLOP

  • MOLOGEN5.27 EUR-13.7%
  • SANTHERA97.20 CHF-11.4%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA97.20 CHF2424.7%
  • WILEX3.15 EUR400.0%
  • FORMYCON17.40 EUR122.2%

FLOP

  • CYTOS0.47 CHF-83.4%
  • MOLOGEN5.27 EUR-57.2%
  • PAION2.09 EUR-55.5%

No liability assumed, Date: 04.03.2015